Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer.
B7 Antigens
Breast Neoplasms
/ genetics
Cation Transport Proteins
Class I Phosphatidylinositol 3-Kinases
/ genetics
DNA, Neoplasm
/ genetics
Evolution, Molecular
Female
Gene Expression Regulation, Neoplastic
/ genetics
Genomics
Humans
Mutation
Neoplasm Proteins
Neurofibromin 1
/ genetics
PTEN Phosphohydrolase
/ genetics
Proteomics
RNA, Neoplasm
/ genetics
Transcriptome
/ genetics
Tumor Suppressor Protein p53
/ genetics
Exome Sequencing
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
received:
15
10
2020
revised:
10
12
2020
accepted:
26
03
2021
pubmed:
31
3
2021
medline:
22
3
2022
entrez:
30
3
2021
Statut:
ppublish
Résumé
Metastatic breast cancer (MBC) is not curable and there is a growing interest in personalized therapy options. Here we report molecular profiling of MBC focusing on molecular evolution in actionable alterations. Sixty-two patients with MBC were included. An analysis of DNA, RNA, and functional proteomics was done, and matched primary and metastatic tumors were compared when feasible. Targeted exome sequencing of 41 tumors identified common alterations in Molecular profiling in MBC reveals multiple common as well as less frequent but potentially actionable alterations. Genomic and transcriptional profiling demonstrates intertumoral heterogeneity and potential evolution of actionable targets with tumor progression. Further work is needed to optimize testing and integrated analysis for treatment selection.
Identifiants
pubmed: 33782032
pii: 1078-0432.CCR-20-4048
doi: 10.1158/1078-0432.CCR-20-4048
pmc: PMC8172429
mid: NIHMS1690798
doi:
Substances chimiques
B7 Antigens
0
CD276 protein, human
0
Cation Transport Proteins
0
DNA, Neoplasm
0
NF1 protein, human
0
Neoplasm Proteins
0
Neurofibromin 1
0
RNA, Neoplasm
0
SLC39A6 protein, human
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
PIK3CA protein, human
EC 2.7.1.137
PTEN Phosphohydrolase
EC 3.1.3.67
PTEN protein, human
EC 3.1.3.67
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3243-3252Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA210950
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR003167
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Clin Proteomics. 2011 Jul 08;8(1):11
pubmed: 21906370
Cancer. 2019 Nov 1;125(21):3714-3728
pubmed: 31318440
Clin Cancer Res. 2018 Jun 15;24(12):2719-2731
pubmed: 29420224
PLoS One. 2014 May 30;9(5):e98187
pubmed: 24878701
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Oncotarget. 2016 Jun 28;7(26):39595-39608
pubmed: 27167191
Elife. 2018 Sep 04;7:
pubmed: 30178746
Ann Oncol. 2019 Apr 1;30(4):558-566
pubmed: 30689707
J Clin Oncol. 2020 Feb 10;38(5):423-433
pubmed: 31841354
Nature. 2012 May 16;486(7403):400-4
pubmed: 22722201
J Breast Cancer. 2015 Sep;18(3):279-84
pubmed: 26472979
PLoS One. 2013 Oct 30;8(10):e77945
pubmed: 24205039
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Clin Cancer Res. 2020 Aug 1;26(15):3947-3957
pubmed: 32312891
Cancer Cell. 2018 Sep 10;34(3):427-438.e6
pubmed: 30205045
Clin Cancer Res. 2020 Nov 15;26(22):5974-5989
pubmed: 32723837
Neoplasia. 2011 Nov;13(11):1019-25
pubmed: 22131877
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
JCO Precis Oncol. 2018;2018:
pubmed: 30035249
Int J Cancer. 2006 Oct 15;119(8):1785-91
pubmed: 16721811
Genome Biol. 2014;15(12):550
pubmed: 25516281
Immunity. 2016 Mar 15;44(3):609-621
pubmed: 26944201
J Natl Cancer Inst. 2015 Apr 11;107(7):
pubmed: 25863335
Nature. 2019 May;569(7757):560-564
pubmed: 31118521
Nat Genet. 2013 Dec;45(12):1446-51
pubmed: 24185510
Clin Proteomics. 2020 Mar 9;17:9
pubmed: 32165870
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Nature. 2016 May 02;534(7605):47-54
pubmed: 27135926
NPJ Breast Cancer. 2018 Oct 12;4:34
pubmed: 30345349
Br J Cancer. 2004 Jul 19;91(2):355-8
pubmed: 15188009
PLoS One. 2015 Dec 07;10(12):e0144162
pubmed: 26641479
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
Cancer Cell. 2020 Mar 16;37(3):387-402.e7
pubmed: 32142667
J Clin Oncol. 2017 Jul 10;35(20):2251-2259
pubmed: 28489509
Genome Med. 2015 Mar 31;7(1):34
pubmed: 25918555
Br J Cancer. 2007 Apr 23;96(8):1258-64
pubmed: 17353917
Int J Cancer. 2021 Mar 15;148(6):1438-1451
pubmed: 32949162
Mol Cancer Ther. 2014 May;13(5):1382-9
pubmed: 24608573
Clin Cancer Res. 2014 Jul 15;20(14):3870-83
pubmed: 24895461
Proteomics Clin Appl. 2015 Oct;9(9-10):928-37
pubmed: 25676683
Nat Genet. 2019 Oct;51(10):1450-1458
pubmed: 31570896
Mol Cancer Ther. 2020 Jul;19(7):1395-1405
pubmed: 32381587
JCO Precis Oncol. 2017;2017:
pubmed: 30320296
Clin Cancer Res. 2014 Apr 1;20(7):1757-1767
pubmed: 24398047
J Clin Invest. 2020 Aug 3;130(8):4252-4265
pubmed: 32657779
Clin Chem. 2015 Mar;61(3):544-53
pubmed: 25626406
Cancer Cell. 2017 Aug 14;32(2):169-184.e7
pubmed: 28810143
Bioinformatics. 2010 Aug 15;26(16):2069-70
pubmed: 20562413
J Clin Invest. 2018 Apr 2;128(4):1371-1383
pubmed: 29480819
Cancer Discov. 2020 Apr;10(4):526-535
pubmed: 31924700
Cancer Discov. 2017 Mar;7(3):302-321
pubmed: 28108460
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Eur J Cancer. 2018 Jan;89:64-71
pubmed: 29232568
Nat Cell Biol. 2018 Sep;20(9):1064-1073
pubmed: 30104724
Cancer Res. 2014 Feb 1;74(3):818-28
pubmed: 24346432
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
J Breast Cancer. 2015 Jun;18(2):160-6
pubmed: 26155292
Lancet Oncol. 2017 Oct;18(10):1360-1372
pubmed: 28800861
Breast Cancer Res Treat. 2018 Feb;167(3):731-740
pubmed: 29110152
BMC Cancer. 2020 Oct 1;20(1):944
pubmed: 33004031